Article
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.
ESMO open - 1 Apr 2026
Dirven I, Bertels C, Moreels Y, Kessels J I, Vanlaer N, Vander Mijnsbrugge A-S, Vounckx M, Dirks I, Raes L, Geeraerts X, Stevens L, von Kemp B, Fasolino G, Awada G, Janssen T, Caljon B, Lefevre T, Everaert H, Rogiers A, Vandemeulebroucke J, Tuyaerts S, Neyns B
Abstract excerpt
BACKGROUND: Most patients with advanced melanoma progress despite standard-of-care treatments. Regorafenib (REGO), an oral multikinase inhibitor with RAF-dimer activity, demonstrated clinical activity in melanoma in retrospective case series and preclinical efficacy in overcoming resistance to BRAF/MEK inhibitors (BRAF/MEKi). This study prospectively evaluated REGO in heavily pretreated advanced melanoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.